Cargando…

Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows

Elucidation of novel peptides presented by human leukocyte antigen (HLA) class I alleles by immunopeptidomics constitutes a powerful approach that can inform the rational design of CD8(+) T cell inducing vaccines to control infection with pathogens such as human immunodeficiency virus type 1 (HIV-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Partridge, Thomas, Nicastri, Annalisa, Kliszczak, Anna E., Yindom, Louis-Marie, Kessler, Benedikt M., Ternette, Nicola, Borrow, Persephone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946011/
https://www.ncbi.nlm.nih.gov/pubmed/29780384
http://dx.doi.org/10.3389/fimmu.2018.00912
_version_ 1783322105027231744
author Partridge, Thomas
Nicastri, Annalisa
Kliszczak, Anna E.
Yindom, Louis-Marie
Kessler, Benedikt M.
Ternette, Nicola
Borrow, Persephone
author_facet Partridge, Thomas
Nicastri, Annalisa
Kliszczak, Anna E.
Yindom, Louis-Marie
Kessler, Benedikt M.
Ternette, Nicola
Borrow, Persephone
author_sort Partridge, Thomas
collection PubMed
description Elucidation of novel peptides presented by human leukocyte antigen (HLA) class I alleles by immunopeptidomics constitutes a powerful approach that can inform the rational design of CD8(+) T cell inducing vaccines to control infection with pathogens such as human immunodeficiency virus type 1 (HIV-1) or to combat tumors. Recent advances in the sensitivity of liquid chromatography tandem mass spectrometry instrumentation have facilitated the discovery of thousands of natural HLA-restricted peptides in a single measurement. However, the extent of contamination of class I-bound peptides identified using HLA immunoprecipitation (IP)-based immunopeptidomics approaches with peptides from other sources has not previously been evaluated in depth. Here, we investigated the specificity of the IP-based immunopeptidomics methodology using HLA class I- or II-deficient cell lines and membrane protein-specific antibody IPs. We demonstrate that the 721.221 B lymphoblastoid cell line, widely regarded to be HLA class Ia-deficient, actually expresses and presents peptides on HLA-C*01:02. Using this cell line and the C8166 (HLA class I- and II-expressing) cell line, we show that some HLA class II-bound peptides were co-purified non-specifically during HLA class I and membrane protein IPs. Furthermore, IPs of “irrelevant” membrane proteins from HIV-1-infected HLA class I- and/or II-expressing cells revealed that unusually long HIV-1-derived peptides previously reported by us and other immunopeptidomics studies as potentially novel CD8(+) T cell epitopes were non-specifically co-isolated, and so constitute a source of contamination in HLA class I IPs. For example, a 16-mer (FLGKIWPSYKGRPGNF), which was detected in all samples studied represents the full p1 segment of the abundant intracellular or virion-associated proteolytically-processed HIV-1 Gag protein. This result is of importance, as these long co-purified HIV-1 Gag peptides may not elicit CD8(+) T cell responses when incorporated into candidate vaccines. These results have wider implications for HLA epitope discovery from abundant or membrane-associated antigens by immunopeptidomics in the context of infectious diseases, cancer, and autoimmunity.
format Online
Article
Text
id pubmed-5946011
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59460112018-05-18 Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows Partridge, Thomas Nicastri, Annalisa Kliszczak, Anna E. Yindom, Louis-Marie Kessler, Benedikt M. Ternette, Nicola Borrow, Persephone Front Immunol Immunology Elucidation of novel peptides presented by human leukocyte antigen (HLA) class I alleles by immunopeptidomics constitutes a powerful approach that can inform the rational design of CD8(+) T cell inducing vaccines to control infection with pathogens such as human immunodeficiency virus type 1 (HIV-1) or to combat tumors. Recent advances in the sensitivity of liquid chromatography tandem mass spectrometry instrumentation have facilitated the discovery of thousands of natural HLA-restricted peptides in a single measurement. However, the extent of contamination of class I-bound peptides identified using HLA immunoprecipitation (IP)-based immunopeptidomics approaches with peptides from other sources has not previously been evaluated in depth. Here, we investigated the specificity of the IP-based immunopeptidomics methodology using HLA class I- or II-deficient cell lines and membrane protein-specific antibody IPs. We demonstrate that the 721.221 B lymphoblastoid cell line, widely regarded to be HLA class Ia-deficient, actually expresses and presents peptides on HLA-C*01:02. Using this cell line and the C8166 (HLA class I- and II-expressing) cell line, we show that some HLA class II-bound peptides were co-purified non-specifically during HLA class I and membrane protein IPs. Furthermore, IPs of “irrelevant” membrane proteins from HIV-1-infected HLA class I- and/or II-expressing cells revealed that unusually long HIV-1-derived peptides previously reported by us and other immunopeptidomics studies as potentially novel CD8(+) T cell epitopes were non-specifically co-isolated, and so constitute a source of contamination in HLA class I IPs. For example, a 16-mer (FLGKIWPSYKGRPGNF), which was detected in all samples studied represents the full p1 segment of the abundant intracellular or virion-associated proteolytically-processed HIV-1 Gag protein. This result is of importance, as these long co-purified HIV-1 Gag peptides may not elicit CD8(+) T cell responses when incorporated into candidate vaccines. These results have wider implications for HLA epitope discovery from abundant or membrane-associated antigens by immunopeptidomics in the context of infectious diseases, cancer, and autoimmunity. Frontiers Media S.A. 2018-04-27 /pmc/articles/PMC5946011/ /pubmed/29780384 http://dx.doi.org/10.3389/fimmu.2018.00912 Text en Copyright © 2018 Partridge, Nicastri, Kliszczak, Yindom, Kessler, Ternette and Borrow. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Partridge, Thomas
Nicastri, Annalisa
Kliszczak, Anna E.
Yindom, Louis-Marie
Kessler, Benedikt M.
Ternette, Nicola
Borrow, Persephone
Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows
title Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows
title_full Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows
title_fullStr Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows
title_full_unstemmed Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows
title_short Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows
title_sort discrimination between human leukocyte antigen class i-bound and co-purified hiv-derived peptides in immunopeptidomics workflows
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946011/
https://www.ncbi.nlm.nih.gov/pubmed/29780384
http://dx.doi.org/10.3389/fimmu.2018.00912
work_keys_str_mv AT partridgethomas discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows
AT nicastriannalisa discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows
AT kliszczakannae discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows
AT yindomlouismarie discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows
AT kesslerbenediktm discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows
AT ternettenicola discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows
AT borrowpersephone discriminationbetweenhumanleukocyteantigenclassiboundandcopurifiedhivderivedpeptidesinimmunopeptidomicsworkflows